4.36 +0.00 (0.00%)
SPPI
Stock Details
Last Trade:4.36 Change:+0.00 (0.00%) Prev Close:4.36 Open: 4.37 Days Range:4.32 – 4.45 52 Week Range: 1.39 - 10.00 Volume:605568 P/E: N/AEPS:-0.73
View AllRecent Alerts 02/10/10
Recent Alert on 02/02/10 at 7:33am
TopoTarget and Spectrum Pharmaceuticals (SPPI) In Deal To Commercialize Belinostat in North America and India
TopoTarget and Spectrum Pharmaceuticals (SPPI) In Deal To Commercialize Belinostat in North America and India
TopoTarget A/S and Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) announced an agreement to co-develop and commercialise belinostat, TopoTarget's lead anticancer drug for cancer in North America and India. Belinostat, an HDAC inhibitor, is in... Read More
Recent Alert on 02/02/10 at 7:33am
TopoTarget and Spectrum Pharmaceuticals (SPPI) In Deal To Commercialize Belinostat in North America and India
TopoTarget and Spectrum Pharmaceuticals (SPPI) In Deal To Commercialize Belinostat in North America and India
Recent Alert on 02/01/10 at 9:33am
Morgan Joseph Adds Spectrum Pharmaceuticals (SPPI) to Trading List; Expect Strong Growth From Zevalin
Morgan Joseph Adds Spectrum Pharmaceuticals (SPPI) to Trading List; Expect Strong Growth From Zevalin
Recent Alert on 01/25/10 at 7:29am
Spectrum Pharma (SPPI) Meets with U.S. FDA for FUSILEV; FDA is Requesting More Data, No More Efficacy Studies
Spectrum Pharma (SPPI) Meets with U.S. FDA for FUSILEV; FDA is Requesting More Data, No More Efficacy Studies
Recent Alert on 01/25/10 at 7:29am
Spectrum Pharma (SPPI) Meets with U.S. FDA for FUSILEV; FDA is Requesting More Data, No More Efficacy Studies
Spectrum Pharma (SPPI) Meets with U.S. FDA for FUSILEV; FDA is Requesting More Data, No More Efficacy Studies
View AllRecent Press Releases
No Recent Press Releases Available
View AllRecent SEC Filings
SEC Filing on 02/08/10 at 5:18pm
Form SC 13G SPECTRUM PHARMACEUTICALS Filed by: Luxor Capital Group, LP
Form SC 13G SPECTRUM PHARMACEUTICALS Filed by: Luxor Capital Group, LP